Outcome key: ● SD/VA ■ Fatal SD/VA
* SD/VA first antipsychotic prescription model adjusted for age, sex, race, state of residence, nursing home residence, prior diagnosis of organic psychosis, and current exposure to cyclic and related antidepressant; Fatal SD/VA first antipsychotic prescription model adjusted for age, sex, race, state of residence, and nursing home residence.
† The color-shading is reflective of CredibleMeds ratings of drugs’ QT-prolonging/TdP-inducing potentials, and is consistent with their coloring scheme: a) red = drugs with a risk of TdP; b) pink = drugs with a possible risk of TdP; and c) not shaded = drugs not rated. Of note, olanzapine was transitioned from a non-rated drug to a drug with possible risk (i.e., pink) on 01/04/2013.
‡ Lower bound of 95% CI = 1.00 when rounded to two decimal places, but p < 0.05
Figure 3: Change-in-estimate adjusted* HRs for sudden cardiac death/ventricular arrhythmia and fatal sudden cardiac death/ventricular arrhythmia, limited to first antipsychotic prescription exposures—each versus olanzapine as the reference exposure.